Behind the research: Jae-Hyuck Shim strives to unlock cure for devastating childhood bone disease
umassmed.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umassmed.edu Daily Mail and Mail on Sunday newspapers.
Guangping Gao and Dan Wang partner with ASC Therapeutics to develop novel gene therapy for maple syrup urine disease
umassmed.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umassmed.edu Daily Mail and Mail on Sunday newspapers.
UMMS establishes gene therapy collaborative research agreement with Pfizer
Researchers will evaluate productivity and quality determinants of recombinant adeno-associated virus production
UMass Medical School Communications April 08, 2021
UMass Medical School has entered into a three-year, collaborative research agreement with Pfizer to evaluate determinants that influence the manufacturing quality and yield of viral vectors used in gene therapy. The research is being jointly conducted by Pfizer and UMMS, with the research at UMMS being performed under the direction of Guangping Gao, PhD, the Penelope Booth Rockwell Professor in Biomedical Research, professor of microbiology & physiological systems, director of the Horae Gene Therapy Center and co-director of the Li Weibo Institute for Rare Diseases Research, and Dan Wang, PhD, assistant professor of RNA therapeutics.
Erik Sontheimer co-leading efforts to develop gene editing toolkit by NIH Somatic Cell Genome Editing Consortium By Jim Fessenden April 07, 2021
Six UMass Medical School scientists are among the members of the National Institutes of Health’s Somatic Cell Genome Editing Consortium to publish a paper in
Nature outlining the program’s goals to accelerate and benchmark the development of safer, more effective methods to edit the genomes of disease-relevant somatic cells in patients. Their research comprising new genome editors, delivery technologies, methods for tracking edited cells in vivo, animal models and human biological systems will be made available as a toolkit that other biomedical researchers can access and apply to an array of disease types and cell tissues as a means of accelerating the clinical development of new therapies for a wide range of illnesses.